At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BIOA BioAge Labs Inc.
Trading 07-31 10:43:53 EDT
10.03
-14.82
-59.66%
High10.81Low8.65Vol3.22M
Open8.77D1 Closing24.85Amplitude8.69%
Mkt Cap444.91MTradable Cap350.39MTotal Shares44.38M
T/O32.25MT/O Rate9.21%Tradable Shares34.95M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Sales of Leqembi® Totaled 29.3 Billion Yen in the Second Quarter 2026
THOMSON REUTERS  ·  07-29 18:30
Sales of Leqembi® Totaled 29.3 Billion Yen in the Second Quarter 2026
How Broad Russell Growth Index Inclusion Could Shape BioAge Labs (BIOA) Investor Exposure
Simply Wall St.  ·  07-10
How Broad Russell Growth Index Inclusion Could Shape BioAge Labs (BIOA) Investor Exposure
Bioage Labs Principal Accounting Officer Shane Barton Disposes of 62,566 Common Shares for $1,578,254.20
Reuters  ·  07-02
Bioage Labs Principal Accounting Officer Shane Barton Disposes of 62,566 Common Shares for $1,578,254.20
BioAge Moves BGE-102 Into Mid-Stage Obesity Heart-Risk Trial, Raising New Investor Focus
TIPRANKS  ·  06-19
BioAge Moves BGE-102 Into Mid-Stage Obesity Heart-Risk Trial, Raising New Investor Focus
Analysts Are Bullish on These Healthcare Stocks: BioAge Labs, Inc. (BIOA), Karyopharm Therapeutics (KPTI)
TIPRANKS  ·  06-17
Analysts Are Bullish on These Healthcare Stocks: BioAge Labs, Inc. (BIOA), Karyopharm Therapeutics (KPTI)
Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA) and Viridian Therapeutics (VRDN)
TIPRANKS  ·  06-17
Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA) and Viridian Therapeutics (VRDN)
BioAge doses first participant in Phase 2 QUELL-CV trial of NLRP3 inhibitor BGE-102
Reuters  ·  06-16
BioAge doses first participant in Phase 2 QUELL-CV trial of NLRP3 inhibitor BGE-102
Bioage Labs - Topline Data From Quell-Cv Trial Anticipated in Second Half of 2026
THOMSON REUTERS  ·  06-16
Bioage Labs - Topline Data From Quell-Cv Trial Anticipated in Second Half of 2026
Bioage Labs Announces First Participant Dosed in Quell-Cv, a Phase 2 Proof-of-Concept Trial of Bge-102, a Novel Oral Nlrp3 Inhibitor, in Patients at Elevated Cardiovascular Risk
THOMSON REUTERS  ·  06-16
Bioage Labs Announces First Participant Dosed in Quell-Cv, a Phase 2 Proof-of-Concept Trial of Bge-102, a Novel Oral Nlrp3 Inhibitor, in Patients at Elevated Cardiovascular Risk
Bioage Labs - to Initiate Phase 1B/2a Trial of Bge-102 in Dme in Mid-2026
THOMSON REUTERS  ·  06-16
Bioage Labs - to Initiate Phase 1B/2a Trial of Bge-102 in Dme in Mid-2026
BioAge Labs Shareholders Reelect Directors, Ratify Auditor
TIPRANKS  ·  06-12
BioAge Labs Shareholders Reelect Directors, Ratify Auditor
BioAge Labs shareholders re-elect three directors at annual meeting
Reuters  ·  06-12
BioAge Labs shareholders re-elect three directors at annual meeting
BioAge Labs posts preclinical data on oral NLRP3 inhibitor BGE-102 in diabetic retinopathy model
Reuters  ·  06-09
BioAge Labs posts preclinical data on oral NLRP3 inhibitor BGE-102 in diabetic retinopathy model
BioAge Labs posts Phase 1 BGE-102 presentation showing anti-inflammatory activity in obesity cohort
Reuters  ·  06-09
BioAge Labs posts Phase 1 BGE-102 presentation showing anti-inflammatory activity in obesity cohort
Roth Capital Partners Initiates BioAge Labs at Buy With $36 Price Target
MT Newswires Live  ·  05-27
Roth Capital Partners Initiates BioAge Labs at Buy With $36 Price Target
BioAge Labs Initiated at Buy by Roth Capital
Dow Jones  ·  05-27
BioAge Labs Initiated at Buy by Roth Capital
BioAge Labs initiated with a Buy at Roth Capital
TIPRANKS  ·  05-27
BioAge Labs initiated with a Buy at Roth Capital
BioAge Labs joins Jefferies Global Healthcare Conference fireside chat
Reuters  ·  05-22
BioAge Labs joins Jefferies Global Healthcare Conference fireside chat
BioAge Labs to Present at Upcoming Investor Conferences
GlobeNewswire  ·  05-22
BioAge Labs to Present at Upcoming Investor Conferences
BTIG Initiates BioAge Labs at Buy With $40 Price Target
MT Newswires Live  ·  05-13
BTIG Initiates BioAge Labs at Buy With $40 Price Target

Introduction

Company Name.
BioAge Labs Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Issue price:
--